Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax Provisions
Others
Ratios

Entrada Therapeutics (TRDA) Profit After Tax: 2022-2025

Historic Profit After Tax for Entrada Therapeutics (TRDA) over the last 4 years, with Sep 2025 value amounting to -$44.1 million.

  • Entrada Therapeutics' Profit After Tax fell 214.52% to -$44.1 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$103.5 million, marking a year-over-year decrease of 288.27%. This contributed to the annual value of $65.6 million for FY2024, which is 1081.69% up from last year.
  • Latest data reveals that Entrada Therapeutics reported Profit After Tax of -$44.1 million as of Q3 2025, which was down 2.39% from -$43.1 million recorded in Q2 2025.
  • Entrada Therapeutics' 5-year Profit After Tax high stood at $55.0 million for Q2 2024, and its period low was -$44.1 million during Q3 2025.
  • Its 3-year average for Profit After Tax is -$4.1 million, with a median of -$9.5 million in 2023.
  • In the last 5 years, Entrada Therapeutics' Profit After Tax surged by 452.05% in 2024 and then slumped by 214.52% in 2025.
  • Over the past 4 years, Entrada Therapeutics' Profit After Tax (Quarterly) stood at -$24.6 million in 2022, then spiked by 61.25% to -$9.5 million in 2023, then skyrocketed by 111.85% to $1.1 million in 2024, then plummeted by 214.52% to -$44.1 million in 2025.
  • Its last three reported values are -$44.1 million in Q3 2025, -$43.1 million for Q2 2025, and -$17.3 million during Q1 2025.